• 1. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 2. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 3. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 4. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 5. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126

Introduction to 5,10-Diazadispiro[2.2.26.23]decane;di-hydrochloride (CAS No: 1235576-70-1)

The compound 5,10-Diazadispiro[2.2.26.23]decane;di-hydrochloride, identified by its CAS number 1235576-70-1, represents a structurally unique and pharmacologically intriguing molecule that has garnered significant attention in the field of medicinal chemistry and drug discovery. This bicyclic compound features a spiro structure composed of two distinct heterocyclic rings interconnected by a single carbon atom, with the presence of two nitrogen atoms embedded within the framework. The dihydrochloride salt form enhances its solubility and stability, making it a promising candidate for further exploration in therapeutic applications.

Recent advancements in chemical biology have highlighted the potential of spirocyclic compounds as scaffolds for developing novel pharmacological agents. The unique conformational rigidity provided by the spiro linkage, combined with the electron-rich nature of the nitrogen-containing rings, suggests that this compound may exhibit favorable interactions with biological targets. Specifically, the 5,10-Diazadispiro[2.2.26.23]decane;di-hydrochloride structure has been hypothesized to interact with enzymes and receptors involved in various metabolic pathways, positioning it as a potential lead compound for treating conditions such as inflammation, neurodegeneration, and metabolic disorders.

In the context of drug design, the spirocyclic core of 5,10-Diazadispiro[2.2.26.23]decane;di-hydrochloride offers several advantages over traditional linear or aromatic scaffolds. The rigid three-dimensional structure can improve binding affinity and selectivity by restricting conformational flexibility, while the nitrogen atoms provide multiple sites for hydrogen bonding and electrostatic interactions with biological targets. These features have prompted researchers to investigate its potential as an inhibitor or modulator of key enzymes such as kinases, proteases, and ion channels.

One particularly compelling area of research involves the exploration of 5,10-Diazadispiro[2.2.26.23]decane;di-hydrochloride as a candidate for treating neurological disorders. Preliminary computational studies have suggested that its molecular framework may mimic natural bioactive molecules involved in neurotransmitter signaling pathways. For instance, the compound’s ability to mimic the binding pocket of enzymes like cyclooxygenase-2 (COX-2) has been computationally modeled, indicating potential anti-inflammatory effects similar to nonsteroidal anti-inflammatory drugs (NSAIDs) but with a distinct mechanism of action.

Furthermore, the dihydrochloride salt form of 5,10-Diazadispiro[2.2.26.23]decane;di-hydrochloride enhances its pharmacokinetic properties by improving solubility in aqueous media and increasing stability under various storage conditions. These characteristics are critical for advancing the compound through preclinical and clinical development pipelines. The enhanced solubility allows for more efficient formulation into oral or injectable dosage forms, while stability improvements reduce concerns about degradation during manufacturing and storage.

Recent experimental studies have begun to validate these theoretical predictions by evaluating the biological activity of 5,10-Diazadispiro[2.2.26.23]decane;di-hydrochloride in vitro and in vivo models. Initial assays have shown promising results in inhibiting inflammatory pathways and reducing oxidative stress in cellular models of neurodegeneration. These findings align with computational models that predicted favorable interactions between the compound’s nitrogen-rich core and biological targets involved in disease pathogenesis.

The synthesis of 5,10-Diazadispiro[2.2.26.23]decane;di-hydrochloride presents both challenges and opportunities for medicinal chemists due to its complex spirocyclic structure. Traditional synthetic approaches often involve multi-step reactions requiring careful control of reaction conditions to ensure regioselectivity and yield optimization. However, advances in organic synthesis techniques such as transition-metal-catalyzed reactions and asymmetric synthesis have made it increasingly feasible to construct complex spirocyclic frameworks efficiently.

The dihydrochloride salt form is particularly noteworthy because it not only improves solubility but also modulates the compound’s pharmacological profile by enhancing its bioavailability and reducing toxicity associated with free base forms. This salt form has been widely used in pharmaceutical formulations to improve drug delivery systems and ensure consistent therapeutic effects.

As research into 5,10-Diazadispiro[2.2.26.23]decane;di-hydrochloride progresses, interdisciplinary collaborations between synthetic chemists, biochemists, and pharmacologists will be essential to fully elucidate its therapeutic potential and optimize its development into a viable drug candidate. The compound’s unique structural features offer a rich foundation for further exploration in medicinal chemistry, particularly in designing next-generation therapeutics targeting complex diseases.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)